24.18 USD
+0.11 (+0.46%)
Taking everything into account, CPRX scores 8 out of 10 in our fundamental rating. CPRX was compared to 525 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. With these ratings, CPRX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year CPRX was profitable.
- In the past year CPRX had a positive cash flow from operations.
- CPRX had positive earnings in each of the past 5 years.
- CPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- CPRX's Return On Assets of 20.69% is amongst the best of the industry. CPRX outperforms 97.14% of its industry peers.
- The Return On Equity of CPRX (23.65%) is better than 96.76% of its industry peers.
- CPRX has a Return On Invested Capital of 21.23%. This is amongst the best in the industry. CPRX outperforms 97.90% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CPRX is above the industry average of 18.07%.
- The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
- CPRX's Profit Margin of 37.64% is amongst the best of the industry. CPRX outperforms 96.76% of its industry peers.
- In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
- With an excellent Operating Margin value of 44.78%, CPRX belongs to the best of the industry, outperforming 99.43% of the companies in the same industry.
- In the last couple of years the Operating Margin of CPRX has grown nicely.
- CPRX's Gross Margin of 85.68% is amongst the best of the industry. CPRX outperforms 88.38% of its industry peers.
- In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
- CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, CPRX has more shares outstanding
- CPRX has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- CPRX has an Altman-Z score of 16.30. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
- CPRX has a Altman-Z score of 16.30. This is amongst the best in the industry. CPRX outperforms 86.67% of its industry peers.
- There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.3 |
ROIC/WACC2.4
WACC8.86%
2.3 Liquidity
- CPRX has a Current Ratio of 6.62. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 6.62, CPRX is doing good in the industry, outperforming 67.62% of the companies in the same industry.
- A Quick Ratio of 6.40 indicates that CPRX has no problem at all paying its short term obligations.
- With a decent Quick ratio value of 6.40, CPRX is doing good in the industry, outperforming 66.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
- CPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.76%, which is quite impressive.
- The Earnings Per Share has been growing by 34.29% on average over the past years. This is a very strong growth
- CPRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.56%.
- Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 36.89% on average per year.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
- The Earnings Per Share is expected to grow by 26.80% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 11.21% on average over the next years. This is quite good.
EPS Next Y24.97%
EPS Next 2Y18.55%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.48%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 14.06, the valuation of CPRX can be described as correct.
- Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.95% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.82. CPRX is valued rather cheaply when compared to this.
- The Price/Forward Earnings ratio is 13.13, which indicates a correct valuation of CPRX.
- Based on the Price/Forward Earnings ratio, CPRX is valued cheaper than 96.95% of the companies in the same industry.
- CPRX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.95.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.06 | ||
| Fwd PE | 13.13 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaply inside the industry as 98.48% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, CPRX is valued cheaper than 97.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.66 | ||
| EV/EBITDA | 7.65 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
- CPRX's earnings are expected to grow with 12.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)0.41
EPS Next 2Y18.55%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
- CPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status for CPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 24.97% in the next year.